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1. Introduction  
In this chapter, we are describing the biology of medulloblastoma influenced by several 
genes/pathways which concur to its pathogenesis. Of note, several levels of regulation  are 
mediated by miRNAs functions, which we dissect their “state of art” to underline their 
crucial roles on controlling cancer development.  
In brain tumours, literatures data, are supporting the values of Cancer Stem Cells (tumor 
propagating cells) and their functions for tumour recurrence for future therapeutic 
treatments. Thus, we link the potential use of miRNAs as “shuttle” to impair Cancer Stem 
Cells in medulloblastoma. 
1.1 Medulloblastoma pathology and implication in medicine. 
Medulloblastoma (MB) is an highly invasive embryonal tumor of the cerebellum, the most 
common malignant brain tumor in children and accounts for more than 25% of childhood 
cancer-related deaths (Wang et al., 2008). MB occurs bimodally, with peaks of incidences 
between 3 and 4 years and 8 and 9 years of age, even if can also arise in adults, showing the 
highest incidence at 20-34 years of age (Crawford et al., 2007). Patients with MB generally 
show symptoms of obstruction of cerebrospinal fluid flow and cerebellar disfunction 
including macrocephaly, vomiting and ataxia (Crawford et al., 2007). It is currently 
classified in several variants: classic, desmoplastic, anaplastic, large-cell and with extensive 
nodularity (Gilbertson and Ellison, 2008). The classic medulloblastoma is composed of small 
round or ellipsoid cells with a high nuclear to cytoplasmic ratio and round to oval or 
triangular hyperchromatic nuclei. The desmoplastic medulloblastoma is defined as having a 
biphasic architecture that consists of regions with dense intercellular reticulin and nodular 
reticulin-free zones, in which tumor cells show a neurocytic phenotype (McManamy et al., 
2007). The Desmoplastic variant represents 50% of adult cases of MB and 15% of children 
related cancer. The original description of the large-cell medulloblastoma drew attention to 
the presence of large round cells with a prominent single nucleolus (Giangaspero et al., 
1999). These cells occupy one end of the range of medulloblastoma cell size and have an area 
2–3 times greater than the mean nuclear area of small round cells in classic tumors 
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(McManamy et al., 2003). The anaplastic medulloblastoma phenotype is applied to tumors 
dominated by combination of marked nuclear pleomorphism and high cell turnover, this 
phenotype is also present in a proportion of non–large-cell medulloblastomas, and 
accounting for almost 10%-22% of all MB tumors (McManamy et al., 2003, Brown et al., 2000, 
Eberhart et al., 2002). Because large-cell and anaplastic medulloblastomas share 
morphophenotypes and an aggressive biological behavior, are often grouped as large-
cell/anaplastic (LCA) medulloblatomas, and represents the most malignant variant 
(Gilbertson and Ellison, 2008). Most medulloblastomas are confined to the posterior fossa, 
however all of the variants can metastasize and 11-43% of patients show disseminated 
disease either along the craniospinal axis, or, more rarely, to extraneural sites (Crawford et 
al., 2007). Disease dissemination rate, patient age and post-operative residual mass represent 
the most important prognostic markers for MB tumors. MB patients are indeed divided into 
risk-stratification groups with patients older than 3 years and gross or near-total surgical 
tumor resection assigned to the average-risk category, which accounts for 60%-70% of all 
MB patients; and patients with disseminated disease at presentation or greater than 1.5 cm2 
of residual tumor mass identified as high-risk category. A third stratification scheme is used 
for patients younger than 3 years old, who generally have worse outcomes mostly due to the 
increased risk of metastatic disease at presentation, increased rate of subtotal resection, and 
not receiving craniospinal radiation therapy (Crawford et al., 2007). Risk-adapted treatments 
are currently adopted in the management of the MB, including surgical tumor resection, 
radiotherapy and chemotherapy. Surgery represents the first approach and a fundamental 
part of MB treatment. It’s aimed to the maximal tumor resection and has shown clear effects 
of survival improvement, particularly in patients with localized disease (Rutkowski et al., 
2005). Addition of radiation therapy to the surgery, has allowed an overall improvement of 
MB patients survival. However, craniospinal axis irradiation often results in severe 
deleterious effects, particularly in infants, thus it is delayed or not given to children younger 
than 3 years (Gilbertson and Ellison, 2008). MB patients belonging to all risk-groups are also 
commonly treated with chemotherapeutic drugs, including vincristine, cyclophosphamide, 
etoposide and methotrexate. For younger patients, chemotherapy is widely used as the 
initial treatment, aimed to delay or avoid radiation therapy. Indeed, intensive postoperative 
chemotherapy alone showed promising results for treatment of young children without 
initial metastases (Rutkowski et al., 2005). Other therapeutic approaches include the use of 
myeloablative doses of chemotherapy followed by autologous stem cell rescue. Early studies 
have reported a survival improvement for patients with high-risk medulloblastoma; 
however, 15% of patients died of treatment-related toxicity (Perez-Martinez et al., 2005). 
Relapse of MB generally manifest within 2 years from the initial therapy in infant, and upon 
5 years in adults. The management of patients with relapsing disease varies and depends on 
a range of factors including the age of the patient and the dissemination rate of the disease. 
However, surgery and possible combined use of chemotherapy and radiotherapy represent 
the leading therapeutic approach (Crawford et al, 2007). The employment of multimodality 
treatment regimens has significantly improved survival rates for MB. However, although 
patients belonging to the average-risk category show an overall survival rate approaching 
70% to 80%, the high-risk patients are generally associated to a very poor prognosis, and MB 
results still incurable for more than one third of patients. Moreover, survivors commonly 
suffer of severe long-term side effects due to the aggressive treatments (Crawford et al., 
2007, Gilbertson and Ellison, 2008).   
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The tumor’s cell origin and the cellular pathways active in MB tumorigenesis are believed to 
play a crucial role in the prognosis and possibly response to therapy of MB (De Bont et al., 
2008). Therefore, a better understanding of the pathology and molecular biology of 
medulloblastoma tumorigenesis is necessary, to identify more efficient therapeutic 
approaches, thereby improving survival and quality of life of MB patients.   
1.2 Cancer stem cells in medulloblastoma 
Once upon a time, cancer was viewed as a homogeneous mass of rapidly proliferating cells, 
and therapeutics were designed to eliminate highly proliferative cells. Recent studies have 
suggested that tumor cells are heterogeneous respect to proliferation and differentiation, 
and that a cell’s proliferative rate may be a poor indicator of its tumorigenic potential. In 
several malignancies, the capacity to initiate and maintain tumor growth has been found to 
reside in a small population of cells called cancer stem cells (CSCs) (Al-Hajj et al.,2004, Reya 
et al., 2001, Wicha et al.,2006). Like normal stem cells, CSCs have the ability to self-renew 
and to give rise to the variety of proliferating and differentiated cells that make up the bulk 
of a tumor. Importantly, CSCs are often relatively quiescent and therefore may not be 
affected by therapies targeting rapidly dividing cells. Elevated expression of transporters 
that pump out chemotherapeutic agents (Donnenberg and Donnenberg, 2005) and an 
increased capacity to repair DNA damage (Bao et al., 2006a) may also contribute to CSCs’ 
ability to survive conventional modes of therapy. The resistance of CSCs to conventional 
therapies may help explain why such therapies often fail: although they may destroy the 
bulk of a tumor, they cannot prevent the surviving CSCs from kicking into action and 
regenerating it again (Al-Hajj et al., 2004; Reya et al., 2001; Wicha et al., 2006). Moreover, the 
properties of CSCs appear to be influenced by both the specific genetic aberrancies in a 
given tumor as well as the stage of disease progression and the types of drugs used to 
challenge tumor growth.  In some cases the number of Cancer Stem Cell able to generate a 
tumorigenic cascade are relatively rare, whereas in others CSCs can constitute a substantial 
proportion of the tumor mass. Moreover the cancer cells within a single tumor exist 
naturally in multiple states of differentiation that show distinct tumor-seeding properties. 
As suggested by Kelly, et al., 2007 and  Quintana et al., 2008, CSCs representation may be a 
function of the cell type of origin, stromal microenvironment, accumulated somatic 
mutations and stage of malignant progression reached by a tumor, indeed selective 
pressures associated with neoplastic progression may lead to a higher frequency and to an 
higher variable properties of functionally defined CSCs in secondary or metastatic stages, as 
well inter-patient and intra-patient heterogeneity of CSCs (Kelly, et al., 2007, Quintana et al., 
2008). The study of CSCs biology is predicated on the ability to accurately assess CSCs 
representation within cancer cell populations. However, measurements of CSCs 
representation are complicated by the quality of the host tissue in which tumor-initiating 
ability is assessed. Thus, animal hosts that offer a hospitable environment to engrafted 
tumor cells will yield measures of CSCs far higher than hosts that fail to do so. Indeed the 
use of immune-compromised mice make  inaccurate the estimation of CSCs number do not 
taking into account that the immune system plays a pivotal role in a number of solid tumors 
(Bonertz et al., 2009). Another aspects of host biology that can affect cancer cell engraftment 
rate include vascularisation at the site of implantation, extracellular matrix constitution, 
growth factor availability. In light of these complexities, CSCs numbers cannot presently be 
stated in absolute terms, but only relative to the animal model used to measure CSC 
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representation. (Piyush et al., 2009) In this view, the CSCs could be viewed as a parody, an 
abnormal deviant of tumorigenic cell influenced by environment stimuli.  
In the 2004, Singh and colleagues were the first to identify prospectively isolated population 
of CSCs in medulloblastoma. These cells were isolated by their ability of expressing the 120-
kDa 5-transmembrane cell surface protein Prominin (CD133), which marks normal human 
neural stem cells. Between 1% and 21% of cells in freshly resected medulloblastomas express 
CD133, but only few as 1000 to 5000 of these CD133+ cells are capable of forming tumors. In 
their experiments Singh and colleagues after cells dissociation, using magnetic bead cell 
sorting, separeted the CD133 positive brain tumour cells from their CD133 negative 
counterparts. Only prominin positive cells when were transplanted into the brains of 
nonobese diabetic/severe combined immunodeficient (NOD/SCID) of six-week-old mice, 
are able to generate a newly tumor. Moreover from analysis of mouse brains following 
CD133+ cells engraftment revealed that as few as 100 CD133+ cells were sufficient for the 
formation of human brain tumours in NOD-SCID mice that were analysed at 12–24 weeks 
post-injection. In the same experiment  they also showed that tumor formed resembles the 
original patient tumour, in fact when injected cells derived from classic medulloblastomas 
showed small round blue cell morphology characteristic histologic structures (Homer–
Wright rosettes), while CD133+ cells derived from a different MB variant, desmoplastic 
medulloblastoma,  recapitulated the cytoarchitecture associated with this subtype.  
The xenograft and the original tumour both expressed the cytoplasmic primitive 
intermediate filaments, neural precursor cell marker, Nestin, Vimentin, the neuronal marker 
βIII-tubulin (TUJI), and show a high proliferative index (MIB-1), which is further increased 
in the xenograft. The astrocyte cell marker GFAP appared to be also expressed in a small 
number of cells in the patient tumour and xenograf. 
Recently Read and colleagues and Ward and colleagues have identified a rare, 
phenotypically primitive, multipotent, and tumorigenic population of Ptc +/-  cells that can 
be propagated by espressing the neural progenitor marker Math1 and Carbohydrate antigen 
(Stage Specific Embrionic Antigen 1, SSEA1) CD15. They have shown that into tumors from 
Ptc +/-/ P53 -/-, an acclaimed genetic MB mouse model, CD15 positive cells are able to 
recapitulate the heterogeneity within the original tumor and in particular are also able to 
generate both CD15 positive  as well as CD15 negative cells, during proliferation, suggesting 
that these cells may sit at the top of a hierarchy of differentiation within the tumor. Those 
cells retain activated Hh and Notch signaling and do not necessarily display Ptc1 loss of 
heterozygosity (LOH) or loss of wild-type (WT) Ptc1 gene expression. Moreover their 
analysis revealed that CD15  cells have a distinct gene expression profile characterized by 
increased expression of genes associated with proliferation and self-renewal and decreased 
expression of genes involved in apoptosis and differentiation. Consistent with this 
expression profile, they also observed that CD15+ cells are more proliferative than CD15- 
cells which are thought to be genetically similar to human nodular/desmoplastic 
medulloblastomas (Read et al., 2009, Ward et al., 2009). 
1.3 Pathways involved in MB cancer stem cells maintenance   
The origins of MB are intrinsically linked to the cerebellum development and MB tumor 
initiating cells can originate from progenitor cells and neuronal stem cells of the cerebellum 
(Yang et al., 2008). Pathways, such as Shh, Wnt, Notch and AKT/PI3K, regulating the 
normal cerebellum development, play a crucial role in the MB tumorigenesis (Marino et al., 
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2005). These pathways are considered to be the master regulators of cerebellum 
development, and several genes belonging to these pathways are frequently mutated or 
deregulated in human MBs. 
The hedgehog signaling (Shh) pathway is pivotal to the development of most vertebrate 
organs and tissues, and has been implicated in birth defects and a multitude of tumour 
types (McMahon et al., 2003, Riobo and Manning, 2007, Wang et al., 2007). Genomic 
alterations in components of the Shh signalling pathway, specifically inactivating mutations 
of PTCH1 and SUFU and/or activating mutations of SMO, have been found in ~15% of 
sporadic medulloblastomas (Pietsch et al., 1997, Raffel et al., 1997, Reifenberger et al., 1998, 
Taylor et al., 2002). Additionally, germline mutations in PTCH1 cause Gorlin’s syndrome, a 
rare congenital condition that is characterized by an increased incidence of several tumour 
types, including medulloblastoma (Hahn et al., 1996). Shh signalling is known to drive 
proliferation in the granule neuron precursors of the cerebellum, and pathway 
dysregulation resulting from genomic alterations of its components presumably drives 
medulloblastoma formation through analogous downstream effects (Pomeroy et al., 2003). 
Cell signaling cascades activated by Wnt proteins (the Wnt signaling pathways) have been 
well conserved throughout evolution. In addition to regulating cellular processes including 
proliferation, differentiation, motility, and survival and/or apoptosis, the Wnt signaling 
pathways play key roles in embryonic development and maintenance of homeostasis in 
mature tissues. Dysregulation of the Wnt pathway has also been linked to the development 
of medulloblastoma. Wnt ligand binds to its receptor frizzled (FZD) leading to the release of 
its downstream effector β–catenin from an inhibitory complex that includes the tumour 
suppressor adenomatous polyposis coli (APC) and the axin proteins. Subsequent nuclear 
accumulation of β–catenin is thought to mediate its tumorigenic functions, presumably 
through the activation of target genes such as MYC, cyclin D1 (CCND1) and Re1–silencing 
transcription factor (REST), which have established roles in cellular proliferation, 
differentiation and inhibition of apoptosis (Eberhart et al., 2000, Rossi et al., 2008). 
Approximately 20% of sporadic medulloblastomas harbour mutations in ApC, AXIN1, 
AXIN2 or CTNNB1 (which encodes β–catenin) (Baeza et al., 2003, Huang et al., 2000, Koch et 
al., 2007, Koch et al., 2001, Zurawe et al., 2008), and a similarly sized fraction (18%) has 
separately been shown to exhibit nuclear β–catenin immunostaining (Eberhart et al., 2000). 
Furthermore, Turcot’s syndrome, which is caused by mutations in APC, is characterized by 
an increased incidence of medulloblastoma and other neuroepithelial tumours. Finally, 
medulloblastomas that are driven by increased Wnt signalling, as shown by nuclear β–
catenin staining, may follow a relatively favourable clinical course (Ellison et al., 2005).  
The Notch pathway is a short-range communication system in which contact between a cell 
expressing a membrane associated ligand and a cell expressing a transmembrane receptor 
sends the receptor-expressing cell (and possibly both cells) a cell fate regulatory signal. The 
Notch pathway has repeatedly been linked to the biology of normal neural stem cells 
(Wang, et al., 2009). Ligand binding to the Notch receptor results in its cleavage and the 
release of the Notch intracellular domain (NICD), the subsequent nuclear translocation of 
which activates various target genes. The Notch pathway is activated in MB (Shih et al., 
2006). Furthermore, increased Notch signalling enhances the efflux of cytotoxic drugs 
through ABC transporters such as ABCG2, a recognized property of stem‑like tumour cells 
that contributes to their resistance to conventional therapies (Bhattacharya et al., 2007, Fan et 
al., 2006). Using fluorescent Hoechst dye, which is also an ABCG2 substrate, stem cells can 
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be effectively sorted by fluorescence‑activated cell sorting (FACS) from brain tumours as a 
‘side population’ (SP) that exhibits a lower level of fluorescence than their non‑stem 
cell‑like counterparts in the ‘main population’ (MP) (Fan et al., 2006,Bleau et al., 2009). 
NICD overexpression increases SP cell number, with Notch pathway inhibition having the 
opposite effect (Fan et al., 2006). Notch signaling also has been linked to MB progression by 
promoting a stem-like state (Jason et al., 20010, Eberhart et al., 2007). Several lines of 
evidence have linked Notch signaling to MB engraftment and progression. Notch pathways 
are upregulated in MB and increased expression of HES1, a target of both the canonical 
notch pathway and the non-canonical shh pathway, is associated with poor prognosis in MB 
patients (Fan et al., 2004, Hallahan et al., 2004, Ingram et al., 2008). Notch2 and Hes5 are 
overexpressed in the shh-activated SmoA1 mouse, suggesting that activation of the shh 
pathway is sufficient to induce notch pathway genes (Hallahan et al., 2004). Previous studies 
using human medulloblastoma cell lines have suggested that Notch signaling is required for 
maintaining subpopulations of progenitor-like cells potentially capable of re-populating 
tumors after initial therapy (Fan et al., 2006), and that notch pathway inhibition can limit 
tumor cell growth (Hallahan et al., 2004, Fan et al., 2006). Recent findings indicats that the 
Notch pathway is not essential for shh-driven medulloblastoma genesis or maintenance 
Notch signaling is not essential for the initiation, engraftment, or maintenance of sonic 
hedgehog pathway driven MB (Hatton et al., 2010). This interpretation is supported by the 
accompanying article that evaluates MB formation in the absence of RBP-J, which is a 
convergence point of all notch pathways (Julian et al., 20010). 
The AKT/PI3K pathway has also been identified as a major effector of stem‑like behaviour 
in malignant brain tumours. Increasing AKT signalling through PTEN loss increases SP cell 
number in mouse glioblastomas, at least partially through the direct activation of ABCG2 
(Bleau et al., 2009). Furthermore, in mouse medulloblastoma models, activation of the PI3K–
AKT–mTOR pathway seems to contribute to the relative resistance of perivascular CSCs to 
therapeutic irradiation (Hambardzumyan et al., 2008). Combining small molecule AKT 
pathway inhibitors with radiotherapy significantly decreases the survival of this resistant 
stem cell‑like pool, indicating a promising avenue for future treatment strategies. 
Supporting these findings, another group has recently reported that PTEN loss and Tp53 
deletion are crucial for the maintenance of self‑renewal in neural stem cells and seem to 
mediate these effects at least in part through the induction of MYC (Zheng et al., 2008).   
The cross talk among these pathways provides an interpretation for the synergy in the 
regulation of MB progression and in CSCs maintenance. Thus the low penetrance in 
medulloblastoma tumor formation in transgenic mice with single pathway deregulation 
would be explained by the need to target multiple pathways to achieve a high frequency of 
tumor formation. Shh signaling synergizes with both Notch and Wnt signaling in 
medulloblastoma development by controlling Notch and Wnt pathway ligand, receptor 
and/or target gene expression. Notch2 and the Notch target gene, HES5, were found 
significantly elevated in Smo-induced medulloblastoma in transgenic mice, showing that 
Shh pathway activation is sufficient to induce Notch pathway signaling (Hallahan et al., 
2004). Expression of several components of the Notch and Wnt signaling pathways, and 
activation of Notch signaling were observed in medulloblastoma from Ptch mice that have 
elevated Shh signaling. Marked downregulation in the expression of Notch2, Jagged1, Hes1, 
in cerebella of developing mice with reduced Shh signaling was also observed, suggesting 
that Shh signaling regulates the expression of these genes (Dakubo et al., 2006). Indeed 
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neuronal precursor cells in the developing cerebellum require activity of the sonic hedgehog 
(Shh) and phosphoinositide-3-kinase (PI3K) pathways for growth and survival. Synergy 
between these signaling pathways are implicated in the neuronal precursor cell cycle 
progression in MB. Recent studies, also show that molecular cross-talk between the beta-
catenin and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways is crucial to 
sustain medulloblastoma pathophysiology, in fact, constitutive activation of 
phosphoinositide-dependent protein kinase 1 (PDK1), Akt, and phosphorylation of GSK-
3beta was detected by immunohistochemistry in all primary medulloblastomas examined. 
Small-molecule inhibitors targeting the PI3K/Akt signaling pathway induced beta-catenin 
signaling by activation of GSK-3beta, resulting in cytoplasmic retention of beta-catenin and 
reduced expression of its target genes cyclin D1 and c-Myc (Baryawno et al., 2009).  
2. MiRNAs functions in cancer 
In addition to protein-encoding genes, a second class of genes producing small noncoding 
RNAs (i.e. microRNAs) has been discovered over the last few years. These short RNAs (18- 
to 24-nucleotides) bind to cis-regulatory elements mainly present in the 3’ UTR of mRNAs, 
resulting in translational inhibition or mRNA degradation (Bartel 2004; Hammond 2006). In 
mammals, miRNAs are predicted to control the activity of ~50% of all protein-coding genes. 
Functional studies indicate that miRNAs participate in the regulation of almost every 
cellular process investigated so far and that changes in their expression are associated with 
many human pathologies (Krol J., et al., 2010; Jeffrey T. DeSano and Liang Xu, 2009). 
Furthermore, microRNAs have been recently shown to be useful tools to silence cancers, 
they might be able to fill this gap through their control of multiple target genes. MicroRNAs 
have been linked to the initiation, progression, and metastasis of human malignancies, with 
some species displaying oncogenic and others tumor suppressive potential (Calin, Croce 
2006; Chen 2005). They are often expressed aberrantly in tumors as compared to normal 
tissues and are likely to contribute to tumorigenesis by dysregulating critical target genes 
(Esquela-Kerscher and Slack 2006; Kent and Mendell 2006; Croce 2009). The case for 
miRNAs as tumor suppressors and oncogenes reflects their loss or gain, respectively, as a 
function of neoplastic transformation, their dysregulation in different tumors, the relevance 
of their mRNA targets to mechanisms underlying tumorigenesis and their ability to alter 
tumorigenesis directly in model cells and organisms (Esquela-Kerscher and Slack 2006; Kent 
and Mendell 2006; Croce 2009; Garzon 2009). Typically, miRNAs that serve as oncogenes are 
present at high levels, which inhibit the transcription of genes encoding tumor suppressors. 
Conversely, tumorsuppressor miRNAs are present at low levels, resulting in the 
overexpression of transcripts encoded by oncogenes (Esquela-Kerscher and Slack 2006).  
The best characterized tumor-suppressor miRNAs are miR-15a and miR-16-1 B-cell chronic 
lymphocytic leukemia (CLL) (Calin, 2002). Tumor suppression by miR-15a and miR-16-1, in 
part, reflects inhibition of the expression of the anti-apoptotic oncogenic protein Bcl-2, which 
is characteristically overexpressed in CLL, promoting the survival of leukemia cells. 
Expression of these miRNAs inhibits cell proliferation, promotes apoptosis of cancer cells, 
and suppresses tumorigenicity both in vitro and in vivo. miR-15a and miR-16-1 function by 
targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A. Down-
regulation of these miRNAs has been also reported in pituitary adenomas, and prostate 
carcinoma (Aqeilan 2009). 
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Another important microRNA is the Let-7 that act as tumor suppressor gene targeting the 
human Ras family of proteins, oncogenes that are commonly mutated in many human 
tumors. Indeed, K-Ras and N-Ras expression in human cells is regulated by let-7 family 
members. Moreover, loss of let-7 expression in human tumors correlates with the 
overexpression of Ras proteins (Johnson 2005). MIR Let-7 its family members are highly 
conserved across species in sequence and function, and misregulation of let-7 leads to a less 
differentiated cellular state and the development (Roush and Slack, 2008).  
The best characterized microRNA that acts as oncogenes is the cluster of miR 17 comprises a 
group of six miRNAs (miR-17-5p, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92) that 
are overexpressed in many types of tumors, including lymphoma, colon, lung, breast, 
pancreas and prostate (O'Donnell et al., 2005; Mendell 2008). Expression of these miRNAs 
promotes cell proliferation, suppresses apoptosis of cancer cells, and induces tumor 
angiogenesis. New work reveals essential functions for these miRNAs not only in tumor 
formation but also during normal development of the heart, lungs, and immune system. The 
human genomic locus encoding these miRNAs, 13q31.3, undergoes amplification in several 
types of lymphoma and solid tumors. The best-characterized target of the miR-17 cluster is 
the E2F1 transcription factor and furthermore, the transcription of the miR-17-92 cluster is 
directly transactivated by c-Myc (O'Donnell et al., 2005; Mendell 2008).  
Moreover, also miRNA-21, plays a crucial role in cancer, in fact it is overexpressed in many 
solid tumors, including breast, colon, lung, prostate and stomach, and in endocrine pancreas 
tumors, glioblastomas and uterine leiomyomas (Si et al., 2007). This miRNA is encoded at 
chromosome 17q23.2, a genetic locus that is frequently amplified in many tumors. The 
tumorigenic effects of miR-21 are mediated, in part, by targeting a number of mediators in 
critical cell-survival pathways. Thus, in glioblastoma cells in vitro, miR-21 modulates the 
expression of the common tumor suppressor PTEN, a central regulator of cell growth, 
proliferation and survival, which is mediated by the in phosphatidylinositol 3-kinase ⁄ Akt 
pathway. Also, miR-21 regulates breast cancer cell growth by reciprocally regulating 
apoptosis and proliferation, in part reflecting regulation of the anti-apoptotic protein, Bcl-2.  
In vitro studies have demonstrated that miR-21 knockdown in tumor cell lines leads to 
increased apoptotic cell death (Seike et al., 2009). Furthermore, miR-21 depletion reduces the 
growth of tumor cell lines xenografts in mice (Si et al., 2007). The transcription of miR-21 
primary RNA is controlled by a conserved upstream enhancer, which has been 
demonstrated to be regulated by gp130-activated Stat3 in myeloma cells, and by AP-1 in 
promyelocitic differentiation induced by TPA (Loffler et al., 2007; Fujita et al., 2008). AP-1 
activity is necessary, but not sufficient, for the induction of miR-21 triggered by Ras (Talotta 
et al., 2009). The miR 21 is recently been studied also in thyroid and lung tumors where it is 
upregulated both in vitro and in vivo by oncogenic Ras. MiR-21 regulation by Ras occurs 
with a delayed kinetic and requires at least two Ras downstream pathways. A screen of 
human thyroid cancers and non-small-cell lung cancers for the expression of miR-21 reveals 
that it is overexpressed mainly in anaplastic thyroid carcinomas, the most aggressive form 
of thyroid cancer, whereas in lung its overexpression appears to be inversely correlated with 
tumor progression. A LNA directed against miR-21 slows down tumor growth in mice. 
Consistently, a search for mRNAs downregulated by miR-21 shows an enrichment for 
mRNAs encoding cell cycle checkpoints regulators, suggesting an important role for miR-21 
in oncogenic Ras-induced cell proliferation (Frezzetti et al.,  Oncogene 2010, in press).  
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2.1 MiRNA involved in Medulloblastoma and cancer stem cells biology 
In MB, up to date, few microRNAs have been studied. MiR-17/92 is best characterized, in 
6% of pediatric MBs it’s found a recurrent amplification of the miR-17/92 polycistron proto-
oncogene (Uziel et al., 2009). Profiling the expression of 427 mature miRNAs in a series of 90 
primary human MBs revealed that components of the miR-17/92 polycistron (miR-92, miR-
19a, and miR-20) are the most highly up-regulated miRNAs in MB. Expression of miR-17/92 
was highest in the subgroup of MBs associated with activation of the sonic hedgehog (Shh) 
signaling pathway compared with other subgroups of MB. MBs in which miR-17/92 was 
up-regulated also had elevated levels of MYC/MYCN expression. Consistent with its 
regulation by Shh, the Shh treatment of primary cerebellar granule neuron precursors 
(CGNP), proposed cells of origin for the Shh-associated MBs, resulted in increased miR-
17/92 expression. In CGNPs, the Shh effector N-myc, but not Gli1, induced miR-17/92 
expression. Ectopic miR-17/92 expression in CGNPs synergized with exogenous Shh to 
increase proliferation and also enabled them to proliferate in the absence of Shh. MiR-17/92 
is a positive effector of Shh-mediated proliferation and that aberrant expression/ 
amplification of this miRNA confers a growth advantage to MBs (Uziel et al., 2009). 
Northcutt and colleagues identified a high-level, focal amplification on chromosome 
13q31.3, which mapped to the same miRNA cluster. The expression of miR-17/92 was most 
elevated in MBs with activated hedgehog signalling and was also associated with elevated 
c-Myc and n-Myc. These studies suggest that aberrant expression of miRNAs encoded by 
the miR-17/92 enhance the growth potential of MB and that miRNA-mediated modulation 
of hedgehog signaling may be an important contributing factor to MB pathogenesis 
(Northcutt et al., 2009).  
A high throughput microRNA expression profiles was performed in human primary MB 
specimens to investigate microRNA involvement in MB carcinogenesis. It has been 
identified specific microRNA expression patterns which distinguish MB differing in 
histotypes (anaplastic, classic and desmoplastic), in molecular features (ErbB2 or c-Myc 
overexpressing tumors) and in disease-risk stratification (Ferretti et al., 2008). They 
proposed a role for miRNAs in modulating hedgehog signaling. In details, they showed that 
miR-125b, miR-326, and miR-324–5p expression was decreased in MB and that the altered 
expression of these miRNAs led to tumor cell proliferation through a hedgehog-dependent 
mechanism. Furthermore, they used high-throughput screening to examine miRNA 
expression profiles in 34 patients with MB. They identified 78 miRNAs with altered 
expression in MB, compared with normal adult and fetal cerebellar cells. Several of the 
identified miRNAs have been implicated in other cancer types including glioblastoma 
(Ciafrè et al., 2005). The majority of these miRNAs were downregulated in MB, supporting a 
role for miRNAs as tumor suppressors. Additionally, they found increased expression of 
miR-9 and miR-125a and that increased expression of these miRNAs was capable of 
decreasing proliferation, augmenting apoptosis, and ultimately promoting arrest of tumor 
growth. The proapoptotic effect was mediated by miR-9 and miR- 125a targeting of the t-
TrkC receptor, which was found in this study to be upregulated in MB cells. The authors 
also found that miR-let7g, miR-19a, miR-106b, and miR-191 were significantly upregulated 
in anaplastic compared with desmoplastic MBs; miR-let7g and miR-106b were differentially 
expressed in desmoplastic compared with classic MBs. Changes in expression of Her2 
(ErbB2) and c-Myc have been demonstrated to impact biological activity and clinical 
features of MB. (Gilbertson et al., 1997; Grotzer et al., 2001; Herms et al., 2000). Ferretti et al. 
examined miRNA expression from MBs overexpressing either Her2 or c-Myc and identified 
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an miRNA signature in each group of MBs. Expression of miR-10b, miR-135a, miR-135b, 
miR-125b and miR-153 was altered in Her2-overexpressing tumors, whereas c-Myc 
overexpressing MBs had expression changes in miR-181b, miR-128a, and miR-128b. 
Additionally, the amount of expression change of 2 miRNAs correlated with disease risk. 
Though miR-31 and miR-153 were downregulated in all MBs, the group found that the 
degree of change was directly proportional to disease severity (Ferretti et al., 2009). 
Although, these data of Ferretti et al., are of interest, miRNAs signature is sicking of 
validation in a large tumors cohorts analysis.  
MiR-124, is another miRNA, preferentially expressed in differentiating and mature neurons 
and in external granule cells of cerebellum that are thought to be cells of origins of MBs 
(Pierson et al., 2008). MiR-124 deregulation is common in MBs, and restoration of its 
function inhibits cell proliferation, suggesting that it may act as a growth suppressor. Two 
target of miR-124 have been studied: cyclin dependent kinase 6 (CDK6) that was identified 
as an adverse prognostic marker in MB and SLC16A1 that may represent a novel therapeutic 
target for treatment of malignant MBs (Pierson J. et al., 2008). SLC16A1, solute carrier family 
16, functions to efflux lactic acid during aerobic glycolysis, and its inhibition resulted in a 
decrease of intracellular pH to a lethal level. This study demonstrates that miR-124 
deregulation is common in medulloblastomas, and restoration of its function inhibits cell 
proliferation, suggesting that miR-124 may act as a growth suppressor, raising the 
possibility that the miR-124/SLC16A1 pathway may represent a novel therapeutic target for 
treatment of malignant medulloblastomas (Li et al., 2009).  
A recent work, demonstrated that miR-30b and miR-30d are amplified in MB and are 
putative oncogenic target(s) of a novel recurrent medulloblastoma amplicon at 8q24.22-
q24.23 (Lu Y. et al., 2009). Furthermore, miR-128a, inhibits growth of medulloblastoma cells 
by targeting the Bmi-1 oncogene. This miRNA alters the intracellular redox state of the 
tumor cells and promotes cellular senescence. MiR-128a has growth suppressive activity in 
medulloblastoma and this activity is partially mediated by targeting Bmi-1. This data has 
implications for the modulation of redox states in cancer stem cells, which are thought to be 
resistant to therapy due to their low ROS states (Venkataraman S, et al., 2010). A complete 
list of miRNAs implicated in MB biology with their function is showed in table 1.  
Our research represents the first work that discovers a microRNA that regulate the Notch 
pathway and depletes the tumor stem cells compartment by using an in vivo therapeutic 
approach using an adenovirus type 5 as carrier, indicating the possibility for the targeting of 
these cells in brain tumors (Garzia et al., 2009). We identified miR199b-5p as targeting HES1, 
the principal Notch effector. We started our study by an in-silico analysis of the mirBase 
targets database (Griffiths-Jones, 2004) towards identification of miRNAs potentially 
targeting HES1. To determine whether HES1 is a target of miR-199b-5p, the HES1 3’ 
untraslated region (UTR) was cloned downstream of a luciferase reporter gene vector; pre-
miR-199b-5p was also cloned in a mammalian expression vector. HEK-293 cells were then 
transfected with the relative luciferase activity showing that miR-199b-5p co-transfection 
decreased reporter gene activity, thus indicating binding with the 3’UTR and destabilisation 
of productive translation of luciferase mRNA. To determine the role of miR-199b-5p in MB 
cell biology, the miR-199b-5p expression construct was transfected into Daoy cells, and 
several stable clones over-expressing miR-199b-5p were selected. These effects of miR-199b-
5p on HES1 protein expression were not restricted to the stable clones or Daoy cells, as 
D283MED cells transiently transfected with the expression construct for miR-199b-5p also 
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showed reduced HES1 levels. Furthermore, we silenced the expression of the miRNA 199b-
5p by 2-ossy-methyl antisense ribonucleotide in daoy cell line overexpressing the miRNA 
199b-5p and we demonstrated that HES1 levels were restored, suggesting 2-OM block of 
HES1 repression by miR-199b-5p, providing further confirmation that miR-199b-5p targets 
HES1 directly. The clones overexpressing the miRNA 199b-5p had reduced proliferation 
rates under standard culture conditions, when compared to the control clone. The clones 
also showed a decreased in S-phase fractions, and an increase in cells in G0-G1 as compared 
to the empty vector clone suggesting that exit from the cell cycle has a role in the reduced 
proliferation of miRNA 199b-5p stable clones.  
We then evaluated the effects of the induction of miR-199b-5p on molecular markers of 
proliferation and differentiation by a real time approach. MAP2, which is mostly expressed 
in mature neurons, was up-regulated in the miR 199b-5p stable clones. Similarly, GFAP 
levels were increased. Among the other genes, GABRA6, a marker of cerebellar granule cell 
differentiation, was also significantly over-expressed in the stable clones. A fine-tuned 
cascade of positive and negative bHLH transcription factors is central to neurogenesis, with 
genes such as MASH1, MATH3 and NGN2 inducing neurogenesis. Both miR-199b-5p stable 
clones showed increases in expression of pro-neural bHLH. In agreement with their 
reduction in proliferation rate, the proliferation markers c-Myc and cyclin D1 were 
decreased demonstrating that these stable clones had an impairment in proliferation rate 
and on the other hand they acquired markers of cerebellar differentiation. We next 
examined in a standard clonogenic assay, if the anchorage independent growth was affected 
by miR-199b-5p. There was a significatively reduction in colony formation potential in miR 
199b-5p stable clones, compared to the empty-vector clone.  
The Notch pathway has been linked to the fraction of MB tumor cells that harbour precursor 
stem-cell markers (Fan et al., 2006), and HES1 has a role in self-renewing of multipotent 
progenitor cells (Nakamura et al., 2000). This side population (SP) of tumor cells has a role 
in the engrafting of a tumor in animal models (Kondo et al., 2004). We thus examined the 
influence of miR-199b-5p on the population of tumor cells that exclude the Hoechst 33342 
dye, a strategy to identify these SP cells. This was determined by flow cytometry in the 
Daoy cell line, the SP was decreased in miR 199b-5p overexpressing clones, as compared 
with the empty vector clones. It is also known that central nervous system tumor stem cells 
express the CD133 antigen, and that these cells are uniquely capable of tumor formation in 
NOD-SCID mice (Singh et al., 2004; Singh et al., 2004). Additionally, the Notch pathway has 
a central role in the self renewing process, with its inhibition leading to depletion of CD133-
positive (CD133+) Daoy cells via induction of apoptosis of progenitor-like cells (Fan et al., 
2006). Recently it was shown that CD133+ Daoy cells promote tumor growth in the flank of 
nude mice, while CD133 - cells do not (Eberhart 2007). For these reasons, we evaluated the 
CD133 positivity of Daoy cells as compared to the miR 199b-5p stable clones showing the 
significatively reduction of the CD133+ cells. This thus demonstrated a role for miR-199b-5p 
in negative regulation of this fraction of tumor-initiating cells. We demonstrate that the miR 
199b-5p depletes the side population compartment in the Daoy cell line and negatively 
regulates MB tumor stem-cell populations positive to CD133 antigen, that are the uniquely 
capable of tumor formation in NOD-SCID mice.  
We further study the role of miRNA 199b-5p in an in vivo tumor model stabilizing the 
previous clones overexpressing miR 199b-5p and control clone with an expression vector 
carrying luciferase cDNA. These stable obtained, were then injected into the left and right 
flanks, respectively, of five athymic nude/nude mice. Tumor growth was evaluated by 
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weekly in-vivo bioluminescence imaging (BLI) of injected mice. Overall, after 8 weeks a 
significant difference in tumor volumes between control flanks and miR-199b-5p flanks was 
seen and also the bioluminescence measurements showed significant reductions in emission 
for the miR-199b-5p sides during tumor growth, as compared with the control sides. MiR-
199b-5p thus can impair tumor formation in vivo in athymic nude mice. To further 
investigate the ability of miR-199b-5p to regulate MB growth, we injected the stable clones 
orthotopically into the fourth ventricle of nude mice of 5 weeks of age. After four weeks of 
in vivo non-invasive monitoring tumor growth by BLI, in mice injected with the clone 
overexpressing the miR 199b-5p, the tumor growth was considerably lower than that 
observed in the control cells injected side. As further confirmation of these effects, we also 
injected the daoy cells infected with an adenovirus coding for miR-199b-5p: in agreement 
with the previous findings, these mice also showed reduced BLI after 4 weeks. 
Hematoxylin-eosine staining of frozen tissues showed tumor mass in the cerebellum of the 
injected animals. Serial parallel frozen histological sections were examined by fluorescence 
microscopy for endogenous green fluorescence protein (GFP) expressed by adenovirus-
infected cells. Then, we evaluated HES1 protein expression by immunohistochemistry 
staining of other paraffin-embedded tissues, using an anti-HES1 antibody. Overall, we 
assessed the levels of persistence of adenovirus expression in infected cells, as the down-
regulation of HES1 expression due to miR199b-5p carrying the adenovirus expression, thus 
following tumor growth over time by BLI. Then, two additional nude mice underwent PET-
CT studies at 12 weeks post-injection, to assess tumor proliferative activity. The BLI data 
were showed also by 3D reconstruction of the orthotopic engraftment. These analyses 
showed significant reduction of tumor mass in the animal injected with the cells infected 
with an adenovirus carrying the miR 199b-5p, as compared to the control mice, with PET-CT 
analyses also providing tumor volumes (0.024 cm3 versus 0.044 cm3, respectively).  Overall, 
these data indicate a beneficial effect of over-expression of miR199b-5p, as a negative 
regulator of tumor growth of MB cells in this orthotopic xenograft nude-mouse model.  
We focus our attention on the expression of the miRNA 199b-5p in human cerebella tissues 
and human MB tissues. We used 13 control samples obtained from the NICHD Brain and 
Tissue Bank for Developmental Disorders, at the University of Maryland, USA. We 
measured miR-199b-5p expression, comparing five cerebellum samples obtained from 0–1-
year-old children with six from 13–16- year-old children by miRNAs PCR real time TaqMan 
assay. MiR-199b-5p showed greater expression in the explants from the younger healthy 
controls. To determine whether miR-199b-5p expression has a role in human MB, samples 
from a cohort of 61 MB patients were analysed. Indeed, it has already been shown that HES1 
protein levels correlate with negative outcome in MB patients (Fan et al., 2004). The whole 
patient population (n= 61) was then divided into two groups, as low versus high miR- 199b-
5p expression, based on the overall median. The distribution of miR-199b-5p expression 
between non-metastatic (M0) and metastatic (M1, M2 and M3) cases showed that miR-199b-
5p expression in the non-metastatic cases was significantly higher than in the metastatic 
cases.  In the subset of patients where follow-up information was available (n= 45), the 
survival curve for the patients who expressed miR-199b-5p at high levels showed a positive 
trend, with better overall survival than the low-expressing patients. These data showing 
down-regulation of miR-199b-5p in metastatic MBs indicates a mechanism of silencing 
through epigenetic or genetic alterations. We thus tested expression of miR-199b-5p by real-
time PCR TaqMan assay in a panel of MB cell lines following induction of de-methylation 
with 5-aza-deoxycytidine. Indeed, two cell lines (Med8a and UW228) showed significant up-
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regulation of miR-199b-5p, thus supporting the hypothesis of epigenetic control of miR-
199b-5p expression. We can conclude that the expression levels of miR-199b-5p in M0 and 
M+ patients, might be due to genetic and epigenetic regulation during carcinogenesis. In 
patients with moderate or high expression of the miRNA 199b-5p, an increase in miR-199b-
5p expression represses HES1, which then leads to an increase in pro-neural bHLHs gene 
expression, driving the cell towards differentiation processes. In patients with moderate or 
low miR-199b-5p expression the genetic or epigenetic control mechanisms, silenced the 
miRNA 199b-5p expression and then HES1 is over-expressed, leading to cell proliferation 
and induction of the SP and hence an increase in CD133+ cancer stem cells. As for many 
other transcription factors, HES1 is a point of integration between and among different 
signal transduction pathways, and its balance of expression determines fundamental cell 
decisions, such as whether or not to start a differentiation program. With this scenario, miR-
199b-5p can be seen as part of the complex Notch signal-transduction pathway, as a fine 
regulator of expression levels of the HES1 bHLH transcription factor. These phenomena 
could be considered to occur in a variety of tissues and cancers where an activated Notch 
pathway is involved.  
The novelties of our work are the finding of a new mechanism of regulation of Notch 
pathway (a fundamental signal transduction in MB development) mediated by a miRNA. 
The miRNA 199b-5p inhibits the Hes1 expression by binding to its 3’UTR, it is known that 
HES1 plays a crucial role in MB biology because high levels of Hes1 protein expression 
correlate with negative outcome in MB patients by negatively influence on their survival 
rate (Fan et al., 2004). Furthermore, the other novelty is the role of the miRNA 199b-5p in the 
impairing of the MB cancer stem cells by decreasing both SP cells and CD133+ cells. In MB, 
the expression of the neural stem cell marker CD133 has been associated with both tumour 
initiation capacity and radioresistance, so it is of fundamental the expression of the miRNA 
199b-5p in directly target of these cells.  
It is well know that one miRNA can target more than hundred of target genes (Peter, 2010), 
this enhance the need to study the so called “off target effect” to exclude possible unwanted 
side effects. We used an in vivo xenographt model performed by Daoy cell line, we can 
further use another cell line of classic histotype to confirm the same data as we evaluated in 
vitro with UW228 and D283 cell lines. Moreover, the miRNA 199b-5p function can be 
evaluated in MB genetic mouse models as Ptc1+/-/p53-/- through a direct injection of the 
adenovirus carrying the miRNA 199b-5p in the cerebellum of mouse. Moreover, the survival 
analysis can be extend in a larger cohort of MB patients with consistent time of follow-up 
data to verify the implication of this miRNA on survival rate.  
2.2 Future research 
We are proceeding with the study of miRNA 199b-5p role in MB, particularly we are 
evaluating the finely regulation mechanism of this miRNA by its target and by other genetic 
and epigenetic changes. Furthermore, we are studying its possible regulation of the other 
marker CD15 of  MB Cancer  Stem Cells. The multiple effects of this miRNA function can be 
due to the inhibition of multiple pathways involved in MB progression, for this reason, we 
are studying all the other possible targets.  
Finally, other miRNAs involved in medulloblastoma pathogenesis and in the impairing of 
MB Cancer Stem Cells are under investigation. One of this, is miRNA 34a, another regulator 
of the Notch pathway (Li et al., 2009) by targeting several pathways/genes of potential 
interests for its therapeutic application.  
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The study of miRNAs in medulloblastoma and in the other brain tumors is still at the 
beginning, but there is strong evidence of miRNAs involvement in medulloblastoma tumor 
development and progression also by regulation of Cancer Stem Cells. We shows our 
hypotesis by a schematic model pictured in figure 1, in which we underline the crucial role 
of miRNAs that impaired the CSCs in MB. These miRNAs act by a directly hit of the CSCs 
that are responsible of the origin and the progression of MB (Fig.1). It is becoming clear that 
miRNAs are essential regulators of many of the key pathways implicated in tumor 
pathogenesis. While adding another layer of complexity, the discovery of the role miRNAs 
in brain tumors has also revealed a new category of therapeutic targets. As miRNA research 
continues to evolve, novel therapeutic targets for the treatment of brain tumors will 






Fig. 1. Schematic model of microRNAs function in MB Cancer Stem Cells.  
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MiRNAs ID MIRNAs function in MB References 
miR-124 Regulation of cell cycle by CKD6 Pierson J, et al., 2008








Hedgehog dependent proliferation Ferretti E., et al., 2008
miR-17-92
Over-expressed in the subgroup of MBs associated with activation of the 
sonic hedgehog (Shh) signaling pathway and elevated levels of MYC/MYCN 
expression 
Uziel T.et al., 2009; 
Northcutt PA. et al., 
2009
miR128 Inhibition of medulloblastoma cells growth by targeting Bmi-1 
Venkataraman S, et 
al., 2010
miR30b, miR30d Target of a novel recurrent medulloblastoma amplicon at 8q24.22-q24.23 Lu Y. et al., 2009
 
Table 1. MiRNAs involved in MB biology 
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